Concomitant tumor resistance

Cancer Letters

Volumn 324, Issue 2, 2012, Pages 133-141

  Chiarella, Paula ^a   Bruzzo, Juan ^a   Meiss, Roberto P ^a   Ruggiero, Raúl A ^a,b  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Anti tumor factors; Concomitant tumor resistance; Metastases; Tumor dormancy; Tyrosine isomers

Indexed keywords

3 (2 HYDROXYPHENYL)ALANINE; META TYROSINE; PHENYLALANINE;

CANCER CELL; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; DISEASE ACTIVITY; EVIDENCE BASED MEDICINE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; ISOMER; METASTASIS INHIBITION; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SHORT SURVEY; TUMOR IMMUNOLOGY; TUMOR MODEL; TUMOR RESISTANCE;

ANIMALIA; MURINAE;

EID: 84864392118     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.021     Document Type: Review

References (85)

1. Ehrlich P. Experimentelle Carcinomstudien an Mausen. Arbeiten aus dem Koiglichen Institut fur Experimentelle Therapie zu Frankfurt/AM 1906, 77-103. Gustav Fischer, Jena, Germany. P. Ehrlich (Ed.).
2. Bashford E., Murray J., Haaland M. General results of propagation of malignant new growths. Third Scientific Report on the Investigation of the Imperial Cancer Research Fund 1908, vol. 3:262-268. Taylor and Francis, London.
3. Woglom W.H. Immunity to transplantable tumors. Cancer Rev. 1929, 4:129-209.
4. Southam C.M. Host defense mechanisms and human cancer. Ann. Inst. Pasteur. 1964, 107:585-597.
5. Brunschwig A., Southam C.M., Levin A. Host resistance to cancer. Clinical experiments by homotransplants, autotransplants and admixture of autologous leucocytes. Ann. Surg. 1965, 162:416-425.
6. Gershon R.K., Carter R.L., Kondo K. On concomitant immunity in tumor-bearing hamsters. Nature (London) 1967, 213:674-676.
7. Lausch R., Rappe F. Concomitant immunity in hamsters bearing DMBA-induced tumor transplants. Int. J. Cancer 1969, 4:226-231.
8. Gorelik E. Concomitant tumor immunity and the resistance to a second tumor Challenge. Adv. Cancer Res. 1983, 39:71-120.
9. Keller R. Repression of lymphatic metastasis by a second implant of the same tumor. Invas. Metast. 1985, 5:295-308.
10. Franco M., Bustuoabad O.D., di Gianni P.D., Goldman A., Pasqualini C.D., Ruggiero R.A. A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic tumours. Br. J. Cancer 1996, 74:178-186.
11. Kaya M., Wada T., Nagoya S., Kawaguchi S., Isu K., Yamashita T. Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy. J. Bone Joint. Surg. Br. 2004, 86:143-147.
12. Demicheli R., Miceli R., Moliterni A., Zambetti M., Hrushesky J.M., Retsky M.W., Valagussa P., Bonadonna G. Breast cancer recurrence dynamics following ajuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann. Oncol. 2005, 16:1449-1457.
13. Sugarbaker E.V., Thornthwaite J., Ketcham A.S. Inhibitory effect of a primary tumor on metastasis. Cancer Invasion and Metastasis, Biological Mechanisms and Therapy 1977, 227-240. Raven, New York. S.B. Day, W. Myers, P. Stansly, S. Garattini, M. Lewis (Eds.).
14. Lange P.H., Hekmat K., Bosl G., Kennedy B.J., Fraley E.E. Accelerated growth of testicular cancer after cytoreductive surgery. Cancer 1980, 45:1498-1506.
15. Gorelik E. Antimetastatic concomitant immunity. Tumor Invasion and Metastasis 1982, 113-131. Martinus Nijhoff Publishers, The Hague. L.A. Liotta, I.R. Hart (Eds.).
16. Bonfil R.D., Ruggiero R.A., Bustuoabad O.D., Meiss R.P., Pasqualini C.D. Role of concomitant resistance in the development of murine lung metastases. Int. J. Cancer 1988, 41:415-422.
17. di Gianni P.D., Franco M., Meiss R.P., Vanzulli S., Piazzon I., Pasqualini C.D., Bustuoabad O.D., Ruggiero R.A. Inhibition of metastases by a serum factor associated to concomitant resistance induced by unrelated murine tumors. Oncol. Rep. 1999, 6:1073-1084.
18. Qadri S.S., Wang J.H., Coffey J.C., Alam M., O'Donnell A., Aherne T., Redmond H.P. Can surgery for cancer accelerate the progression of secondary tumors within residual minimal disease at both local and systemic levels?. Ann. Thorac. Surg. 2005, 80:1046-1050.
19. Peeters C.F., de Waal R.M., Wobbes T., Ruers T.J. Metastatic dormancy imposed by the primary tumor: does it exist in humans?. Ann. Surg. Oncol. 2008, 15:3308-3315.
20. Beecken W.D., Engl T., Jonas D., Blaheta R.A. Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy. Int. J. Mol. Med. 2009, 23:261-266.
21. Chen J., Sprouffske K., Huang Q., Maley C.C. Solving the puzzle of metastasis: the evolution of cell migration in neoplasms. PLOS one 2011, 6:e17933.
22. Tyzzer E.E. Factors in the production and growth of tumor metastases. J. Med. Res. 1913, 28:309-332.
23. Tadenuma K., Okonogi S. Experimentelle Untersuchugen uber Metastasen bei Mausecarcinom. Z. Krebsforsch 1924, 21:168-172.
24. Ketcham A.S., Kinsey D.L., Wexler H., Mantel N. The development of spontaneous metastases after the removal of a "primary" tumor. Cancer 1961, 14:875-882.
25. Guba M., Cernaianu G., Koehl G., Geissier E.K., Jauch K.W., Anthuber M., Falk W., Steinbauer M. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res. 2001, 61:5575-5579.
26. Ebos J.M.L., Lee C.R., Cruz-Muñoz W., Bjarnason G.A., Christensen J.K., Kerbel R.S. Cancer Cell 2009, 15:232-239.
27. Demicheli R., Retsky M.W., Hrushesky W.J.M., Baum M., Gukas I.D. The effects of surgery on tumor growth: a century of investigations. Annal. Oncol. 2008, 19:1821-1828.
28. Iversen P., Madsen P.O., Corle D.K. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate: twenty three year follow-up of a prospective randomized study. Scan. J. Urol. Neph. 1995, 172:65-72.
29. Demicheli R., Valagussa P., Bonadonna G. Does surgery modify growth kinetics of breast cancer micrometastases?. Br. J. Cancer 2001, 85:490-492.
30. Retsky M.W., Demicheli R., Hrushesky W.J.M., Baum M., Gukas I.D. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 2008, 116:730-741.
31. Karrison T.G., Ferguson D.J., Meier P. Dormancy of mammary carcinoma after mastectomy. J. Natl. Cancer Inst. 1999, 99:80-85.
32. Nguyen D.H., Truong P.T. A debate on locoregional treatment of the primary tumor in patients presenting with stage IV breast cancer. Expert Rev. Anticancer Ther. 2011, 11:1913-1922.
33. Clark W.E., Elder D.E., Guerry D.I.V., Braitman L.E., Trock B.J., Schultz D., Synnestvedt M., Halpern A.C. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 1989, 81:1893-1904.
34. Hoskins W.J. The influence of cytoreductive surgery on progression -free interval and survival in epithelial ovarian cancer. Baillieres Clin. Obstet. Gynecol. 1989, 3:59-71.
35. Coffey J.C., Wang J.H., Smith M.J.F., Bouchier-Hayes D., Cotter T.G., Redmond H. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 2003, 4:760-768.
36. Maniwa Y., Kanki M., Okita Y. Importance of the control of lung recurrence soon after surgery of pulmonary metastases. Am. J. Surgery 2000, 179:122-125.
37. Mitsudomi T., Maruyama R., Saitoh G., Hamatake M., Fukuyama Y., Yaita H., Ishida T., Sugimachi K. Kinetic analysis of recurrence and survival after potentially curative resection of non-small cell lung cancer. J. Surg. Oncol. 1996, 63:159-165.
38. Lacy A.M., García-Valdecasas J.C., Delgado S., Castells A., Taurá P., Piqué J.M., Visa J. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomized trial. Lancet 2002, 359:2224-2229.
39. DeLisser H.M., Keirns C.C., Clinton E.A., Margolis M.L. "The air got to it": exploring a belief about surgery for lung cancer. J. Natl. Med. Assoc. 2009, 101:765-771.
40. Ando K., Hunter N., Peters L. Immunologically nonspecific enhancement of artificial lung metastases in tumor-bearing mice. Cancer Immun. Immunother. 1979, 6:151-156.
41. Janik P., Bertram J., Szaniawska B. Modulation of lung tumor colony formation by a subcutaneously growing tumor. J. Natl. Cancer Inst. 1981, 66:1155-1158.
42. McAllister S.S., Gifford A.M., Greiner A.L., Kelleher S.P., Saelzler M.P., Ince T.A., Reinhardt F., Harris L.N., Hylander B.L., Repasky E.A., Weinberg R.A. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005.
43. Elkabets M., Gifford A.M., Scheel C., Nilsson B., Reinhardt F., Bray M.A., Carpenter A.E., Jirström K., Magnusson K., Ebert B.L., Pontén F., Weinberg R.A., McAllister S.S. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblast in mice. J. Clin. Invest. 2011, 12:784-799.
44. Vizel M., Oster M.W., Austin J.H. Spontaneous regression of a pulmonary metastasis after nephrectomy for renal cell carcinoma. J. Surg. Oncol. 1979, 12:175-180.
45. Lokick J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am. J. Clin. Oncol. 1997, 20:416-418.
46. Wyczolkowski M., Klima W., Bieda W., Walask K. Spontaneous regression of hepatic metastases after nephrectomy and mastectomy of renal cell carcinoma. Urol. Int. 2001, 66:119-120.
47. Lekanidi K., Vlachou P.A., Morgan B., Vasanthan S. Spontaneous regression of metastatic renal cell carcinoma: case report. J. Med. Case Reports 2007, 1:89.
48. Bruzzo J., Chiarella P., Meiss R.P., Ruggiero R.A. Biphasic effect of a primary tumor on the growth of secondary tumor implants. J. Cancer Res. and Clin. Oncol. 2010, 136:1605-1615.
49. Moroson H., Ioachim H.L. Protection by grafts of embryonal rat tissues (teratomas) against induction and transplantation of malignant tumors. Cancer Res. 1995, 55:3664-3668.
50. Bustuoabad O.D., di Gianni P.D., Franco M., Kordon E.C., Vanzulli S.I., Meiss R.P., Grion L.C., Díaz G.S., Nosetto S.H., Hockl P., Lombardi M.G., Pasqualini C.D., Ruggiero R.A. Embryonal mass and hormone-associated effects of pregnancy inducing a differential growth of four murine tumors. Oncol. Res. 2002, 13:147-160.
51. Ruggiero R.A., Bustuoabad O.D., Cramer P., Bonfil R.D., Pasqualini C.D. Correlation between seric antitumor activity and concomitant resistance in mice bearing non-immunogenic tumors. Cancer Res. 1990, 50:7159-7165.
52. Jirtle R.L., Michalopoulus G. Effects of partial hepatectomy on transplanted Hepatocytes. Cancer Res. 1982, 42:3000-3004.
53. Joseph B., Berishvili E., Benten D., Kumaran V., Liponava E., Bhargava K., Palestro C., Kakabadze Z., Gupta S. Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions. Nat. Med. 2004, 10:749-753.
54. North R.J. The murine antitumor immune response and its therapeutic Manipulation. Adv. Immunology 1984, 35:89-155.
55. Ruggiero R.A., Bustuoabad O.D., Bonfil R.D., Meiss R.P., Pasqualini C.D. "Concomitant immunity" in murine tumours of non-detectable immunogenicity. Br. J. Cancer 1985, 51:37-48.
56. DeWys W.D. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res. 1972, 32:374-379.
57. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
58. Bustuoabad O.D., Genovese J.A., Pasqualini C.D. Abrogation of concomitant tumor immunity in mice. Com. Biol. (Argentina) 1984, 2:423-430.
59. Nakahara W., Fukuoka F. The newer concept of cancer toxin. Adv. Cancer Res. 1958, 5:157-177.
60. Ruggiero R.A., di Gianni P.D., Franco M., Bustuoabad O.D. Resistencia concomitante antitumoral. Medicina (Bs.As.) 1996, 56:57-64.
61. Franco M., Bustuoabad O.D., di Gianni P.D., Meiss R.P., Vanzulli S., Buggiano V., Pasqualini C.D., Ruggiero R.A. Two different types of concomitant resistance induced by murine tumors: morphological aspects and intrinsic mechanisms. Oncol. Rep. 2000, 7:1053-1063.
62. Meiss R.P., Bonfil R.D., Ruggiero R.A., Pasqualini C.D. Histologic aspects of concomitant resistance induced by nonimmunogenic tumors. J. Natl. Cancer Inst. 1986, 76:1163-1175.
63. Ruggiero R.A., Bruzzo J., Chiarella P., di Gianni P., Isturiz M.A., Linskens S., Speziale N., Meiss R.P., Bustuoabad O.D., Pasqualini C.D. Tyrosine isomers mediate the classical phenomenon of concomitant tumor resistance. Cancer Res. 2011, 71:7113-7124.
64. Prehn R.T. Two competing influences that may explain concomitant tumor Resistance. Cancer Res. 1993, 53:3266-3269.
65. Gurer-Orhan H., Ercal N., Mare S., Pennathur S., Orhan H., Heinecke J.W. Misincorporation of free m-tyrosine into cellular proteins: a potential cytotoxic mechanism for oxidized amino acids. Biochem. J. 2006, 395:277-284.
66. Bertin C., Weston L.A., Huang T., Jander G., Owens T., Meinwald J., Schroeder F.C. Grass roots chemistry: meta-tyrosine, an herbicidal nonprotein aminoacid. Proc. Natl. Acad. Sci. USA 2007, 104:16964-16969.
67. Chiarella P., Vulcano M., Bruzzo J., Vermeulen M., Vanzulli S., Maglioco A., Camerano G., Palacios V., Fernández G., Fernández Brando R., Isturiz M.A., Dran G.I., Bustuoabad O.D., Ruggiero R.A. Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol. Immunother. 2008, 57:701-718.
68. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., Shono Y., Kitabatake M., Kakimi K., Mukaida N., Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
69. Kusmartsev S., Gabrilovich D.I. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 2006, 55:237-245.
70. Yu P., Rowley D.A., Fu Y., Schreiber H. The role of stroma in immune recognition and destruction of well-established tumors. Curr. Opin. Immunol. 2006, 18:226-231.
71. Gabrilovich D.I., Nagaraj S. Myeloid-derived-suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
72. Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.I., Cheng P., Cho H., Celis E., Quiceno D.G., Padhya T., McCaffrey T.V., McCaffrey J.C., Gabrilovich D.I. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010, 207:2439-2453.
73. Ruggiero R.A., Bruzzo J., Chiarella P., Bustuoabad O.D., Meiss R.P., Pasqualini C.D. Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control. Cancer Res. 2012, 72:1043-1050.
74. Glick A.B., Yuspa S.H. Tissue homeostasis and the control of the neoplastic phenotypein epithelial cancers. Semin. Cancer Biol. 2005, 15:75-83.
75. Ruggiero R.A., Bustuoabad O.D. The biological sense of cancer: a hypothesis. Theor. Biol. Med. Mod. 2006, 3:43.
76. Laird A.K., Tyler S.A., Barton A.D. Dynamics of normal growth. Growth 1965, 29:233-248.
77. Laird A.K. Dynamics of tumor growth: comparison of growth rates and extrapolation of growth curve to one cell. Br. J. Cancer 1965, 29:278-291.
78. Prehn R.T. The inhibition of tumor growth by tumor mass. Cancer Res. 1991, 51:2-4.
79. Miller B.E., Miller F.R., Wilburn D.J., Hepner G.H. Analysis of tumor cell composition in tumors composed of paired mixtures of mammary tumor cell lines. Br. J. Cancer 1987, 56:561-566.
80. Miller B.E., Miller F.R., Hepner G.H. Therapeutic perturbation of the tumor ecosystemin reconstructed heterogeneous mouse mammary tumors. Cancer Res. 1989, 49:3747-3753.
81. Korn J.H., Downie E. Clonal interactionsin fibroblast proliferation: recognition of self vs non-self. J. Cell Physiol. 1989, 141:437-440.
82. El Saghir N.S., Elhajj I.I., Geara F.B., Hourani M.H. Trauma-associated growth of suspected micrometastases. B.M.C. Cancer 2005, 5:94.
83. Ossowski L., Aguirre-Ghiso J.A. Dormancy of metastatic melanoma, pigment cell. Melanoma Res. 2010, 23:41.
84. Zhao T., Xia W.H., Zheng M.Q., Lu C.Q., Han X., Sun Y.J. Surgical excision promotes tumor growth and metastasis by promoting expression of MMP-9 and VEGF in a breast cancer model. Exp. Oncol. 2008, 30:60-64.
85. Park Y., Kitahara T., Takagi R., Kato R. Does surgery for breast cancer induce angiogenesis and thus promote metastasis?. Oncology 2011, 81:199-205.